Afirma GEC与GSC评估细胞学不确定甲状腺结节的真实世界比较
该研究回顾性比较了Afirma基因表达分类器(GEC)与基因测序分类器(GSC)在Bethesda III和IV甲状腺结节中的表现。GSC的良性判读率显著高于GEC(67.8% vs 41%,P < .001),且特异性(94% vs 60%,P < .001)和阳性预测值(85.3% vs 40%,P < .001)均显著提高,手术率从47.8%降至34.7%(P = .025)。
要点
- GSC良性判读率67.8%,显著高于GEC的41%(P < .001)。
- GSC特异性94%、PPV 85.3%,均显著优于GEC(P < .001)。
- GSC组手术率34.7%,低于GEC组的47.8%(P = .025)。
核心结论
- GSC将更多不确定结节重新分类为良性,提高了检测的特异性和阳性预测值,并减少了诊断性手术。
研究设计与样本
- 回顾性分析2011年12月至2018年9月在一个学术中心接受GEC或GSC检测的Bethesda III和IV甲状腺结节。
- 比较良性判读率(BCR)和手术结局,并对手术切除结节收集组织病理学数据以计算检测性能指标。
主要发现
- 总体BCR:GEC组41%(73/178),GSC组67.8%(82/121),P < .001。
- 以Hürthle细胞细胞学为主的标本中,BCR:GEC组22%(6/27),GSC组63.2%(12/19),P = .005。
- 总体手术率从GEC组的47.8%降至GSC组的34.7%(P = .025)。
- GEC良性判读的结节中1例、GSC良性判读的结节中3例经手术切除证实为恶性。
- GSC特异性94% vs GEC 60%(P < .001),PPV 85.3% vs 40%(P < .001);敏感性97.0% vs 90.6%、NPV 98.6% vs 96.3%,差异无统计学意义。
关键数值与推荐
- GSC良性判读率67.8%(82/121),GEC为41%(73/178),P < .001。
- GSC特异性94%、PPV 85.3%,GEC分别为60%、40%,P均< .001。
- GSC敏感性90.6%、NPV 96.3%,GEC分别为97.0%、98.6%,差异无统计学意义。
- GSC组手术率34.7%,GEC组47.8%,P = .025。
临床怎么用
- 对于细胞学不确定的甲状腺结节,GSC较GEC能更有效识别良性结节,降低不必要的手术。
- GSC良性判读后仍需结合临床随访,因研究中GSC良性结节有3例经手术证实为恶性。
局限性
- 回顾性单中心分析,样本量有限,可能存在选择偏倚。
- 仅对手术切除的结节有组织病理学数据,未手术结节缺乏验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Molecular tests have improved the accuracy of preoperative diagnosis of indeterminate thyroid nodules. The Afirma Gene Sequencing Classifier (GSC) was developed to improve the specificity of the Gene Expression Classifier (GEC). Independent studies are needed to assess the performance of GSC. OBJECTIVE: The aim was to compare the performance of GEC and GSC in the assessment of indeterminate nodules. DESIGN, SETTINGS, AND PARTICIPANTS: Retrospective analysis of Bethesda III and IV nodules tested with GEC or GSC in an academic center between December 2011 and September 2018. Benign call rates (BCRs) and surgical outcomes were compared. Histopathologic data were collected on nodules that were surgically resected to calculate measures of test performance. RESULTS: The BCR was 41% (73/178) for GEC and 67.8% (82/121) for GSC (P < .001). Among specimens with dominant Hürthle cell cytology, the BCR was 22% (6/27) for GEC and 63.2% (12/19) for GSC (P = .005). The overall surgery rate decreased from 47.8% in the GEC group to 34.7% in the GSC group (P = .025). One GEC-benign and 3 GSC-benign nodules proved to be malignant on surgical excision. GSC had a statistically significant higher specificity (94% vs 60%, P < .001) and positive predictive value (PPV) (85.3% vs 40%, P < .001) than GEC. While sensitivity and negative predictive value (NPV) dropped with GSC (97.0% vs 90.6% and 98.6% vs 96.3%, respectively), these differences were not significant. CONCLUSIONS: GSC reclassified more indeterminate nodules as benign and improved the specificity and PPV of the test. These enhancements appear to be resulting in fewer diagnostic surgeries.
引用
- San Martin VT, Lawrence L, Bena J, et al. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules. J Clin Endocrinol Metab. 2020. PMID: 31665322. doi:10.1210/clinem/dgz099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。